| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
University of Pittsburgh, Pittsburgh, Pennsylvania 15261
The effect of removal of a primary tumor on the kinetics of cells in a metastasis was evaluated using six different tumors (C3H, MXTa, MXTb, MC54, CD8, and 3LL) which varied relative to their origin, histology, and the strain of mice in which they were carried. There was an increase in the labeling index (LI) of a distant tumor focus ("metastasis") associated with the removal of each of the tumor types and unrelated to operative and anesthetic trauma. Information presented supports the presence of a serum growth factor as being responsible for the phenomenon. Serum obtained from mice following removal of a tumor, when transferred to a recipient with the same type of tumor as in the donor, resulted in an increase in the LI of the tumor. Multiple injections of serum failed to add to the increase but did prolong its presence, suggesting that there is a finite population of cells, most likely in the G1-G0 phase, which are capable of responding to the stimulating factor.
The transfer of serum obtained following removal of a tumor type different from that in recipients resulted in findings which indicate that tumors producing a stimulating growth factor are those capable of responding to it. Serum obtained from animals with unremoved tumors or less than 18 h after removal failed to substantially augment the LI of tumors in recipients. It is postulated that the growth factor released by a tumor is in an inactive form which becomes activated over time.
Observations indicate that medium conditioned by the growth of C3H tumor contains a growth-stimulating factor which is capable of increasing the LI of a C3H tumor in a recipient in a fashion similar to that obtained following tumor removal. That finding indicates the capability of the tumor to elaborate growth-stimulating material which may be similar to that found in serum.
The findings presented refute the premise that removal of a primary tumor is a local phenomenon with no other biological consequences. They indicate that, following primary tumor removal, metastatic behavior may be affected by an interplay of growth factor(s) which can influence the outcome of a host to its tumor.
1 This investigation was supported in part by a USPHS Grant R01-CA-14972 awarded by the National Cancer Institute, Department of Health and Human Services.
2 To whom requests for reprints should be addressed, at Room 914, Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261.
Received 8/15/88. Revised 12/21/88. Accepted 1/13/89.
This article has been cited by other articles:
|
|
 |
|
  R. Demicheli, M. W. Retsky, W. J. M. Hrushesky, M. Baum, and I. D. Gukas The effects of surgery on tumor growth: a century of investigations Ann. Onc., June 10, 2008; (2008) mdn386v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Becker, R. E. Ellsworth, B. Deyarmin, H. L. Patney, R. M. Jordan, J. A. Hooke, C. D. Shriver, and D. L. Ellsworth The Genomic Heritage of Lymph Node Metastases: Implications for Clinical Management of Patients with Breast Cancer Ann. Surg. Oncol., April 1, 2008; 15(4): 1056 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Belletti, J. S. Vaidya, S. D'Andrea, F. Entschladen, M. Roncadin, F. Lovat, S. Berton, T. Perin, E. Candiani, S. Reccanello, et al. Targeted Intraoperative Radiotherapy Impairs the Stimulation of Breast Cancer Cell Proliferation and Invasion Caused by Surgical Wounding Clin. Cancer Res., March 1, 2008; 14(5): 1325 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ohta, R. Waseda, H. Minato, N. Endo, Y. Shimizu, I. Matsumoto, and G. Watanabe Surgical Results in T2N0M0 Nonsmall Cell Lung Cancer Patients With Large Tumors 5 cm or Greater in Diameter: What Regulates Outcome? Ann. Thorac. Surg., October 1, 2006; 82(4): 1180 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum Primary Systemic Therapy of Breast Cancer Oncologist, June 1, 2006; 11(6): 574 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gianni, J. Baselga, W. Eiermann, V. Guillem Porta, V. Semiglazov, A. Lluch, M. Zambetti, D. Sabadell, G. Raab, A. Llombart Cussac, et al. Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy Clin. Cancer Res., December 15, 2005; 11(24): 8715 - 8721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Demicheli, R. Miceli, A. Moliterni, M. Zambetti, W. J. M. Hrushesky, M. W. Retsky, P. Valagussa, and G. Bonadonna Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process Ann. Onc., September 1, 2005; 16(9): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mauri, N. Pavlidis, and J. P. A. Ioannidis Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis J Natl Cancer Inst, February 2, 2005; 97(3): 188 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Cleator, A. Makris, S. E. Ashley, R. Lal, and T. J. Powles Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival Ann. Onc., February 1, 2005; 16(2): 267 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colleoni, G. Viale, D. Zahrieh, G. Pruneri, O. Gentilini, P. Veronesi, R. D. Gelber, G. Curigliano, R. Torrisi, A. Luini, et al. Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment Clin. Cancer Res., October 1, 2004; 10(19): 6622 - 6628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Estevez and W. J. Gradishar Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3249 - 3261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Demicheli, G. Bonadonna, W. J.M. Hrushesky, M. W. Retsky, and P. Valagussa Menopausal Status Dependence of Early Mortality Reduction Due to Diagnosis of Smaller Breast Cancers (T1 v T2-T3): Relevance to Screening J. Clin. Oncol., January 1, 2004; 22(1): 102 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Baines Mammography Screening: Are Women Really Giving Informed Consent? J Natl Cancer Inst, October 15, 2003; 95(20): 1508 - 1511. [Full Text] [PDF]
|
|
|
|
|
|
C. Shannon, S. Ashley, and I.E. Smith Does Timing of Adjuvant Chemotherapy for Early Breast Cancer Influence Survival? J. Clin. Oncol., October 15, 2003; 21(20): 3792 - 3797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colleoni, G. Curigliano, I. Minchella, G. Peruzzotti, F. Nole, G. Mazzarol, G. Renne, L. Orlando, A. Rocca, P. Veronesi, et al. Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase Ann. Onc., October 1, 2003; 14(10): 1477 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Hormbrey, C. Han, A. Roberts, D. A. McGrouther, and A. L. Harris The Relationship of Human Wound Vascular Endothelial Growth Factor (VEGF) After Breast Cancer Surgery to Circulating VEGF and Angiogenesis Clin. Cancer Res., October 1, 2003; 9(12): 4332 - 4339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. Danforth Jr, K. Cowan, R. Altemus, M. Merino, C. Chow, A. Berman, U. Chaudhry, C. Shriver, S. M. Steinberg, and J. Zujewski Preoperative FLAC/Granulocyte-Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer: A Prospective Randomized Trial Ann. Surg. Oncol., July 1, 2003; 10(6): 635 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Wolff and N. E. Davidson Preoperative Therapy in Breast Cancer: Lessons from the Treatment of Locally Advanced Disease Oncologist, June 1, 2002; 7(3): 239 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Love, N. B. Duc, N. V. Dinh, T.-Z. Shen, T. C. Havighurst, D. C. Allred, and D. L. DeMets Mastectomy and Oophorectomy by Menstrual Cycle Phase in Women With Operable Breast Cancer J Natl Cancer Inst, May 1, 2002; 94(9): 662 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. van der Hage, C. J.H. van de Velde, J.-P. Julien, M. Tubiana-Hulin, C. Vandervelden, and L. Duchateau Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902 J. Clin. Oncol., November 15, 2001; 19(22): 4224 - 4237. [Abstract] [Full Text]
|
|
|
|
|
|
M. Colleoni, S. Gelber, A. S. Coates, M. Castiglione-Gertsch, R. D. Gelber, K. Price, C.-M. Rudenstam, J. Lindtner, J. Collins, B. Thurlimann, et al. Influence of Endocrine-Related Factors on Response to Perioperative Chemotherapy for Patients With Node-Negative Breast Cancer J. Clin. Oncol., November 1, 2001; 19(21): 4141 - 4149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Feldman, L. Tamarkin, G. F. Paciotti, B. W. Simpson, W. M. Linehan, J. C. Yang, W. E. Fogler, E. M. Turner, H. R. Alexander Jr., and S. K. Libutti Serum Endostatin Levels Are Elevated and Correlate with Serum Vascular Endothelial Growth Factor Levels in Patients with Stage IV Clear Cell Renal Cancer Clin. Cancer Res., December 1, 2000; 6(12): 4628 - 4634. [Abstract] [Full Text]
|
|
|
|
|
|
A. C. Wolff and N. E. Davidson Primary Systemic Therapy in Operable Breast Cancer J. Clin. Oncol., April 7, 2000; 18(7): 1558 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colleoni, M. Bonetti, A. S. Coates, M. Castiglione-Gertsch, R. D. Gelber, K. Price, C.-M. Rudenstam, J. Lindtner, J. Collins, B. Thurlimann, et al. Early Start of Adjuvant Chemotherapy May Improve Treatment Outcome for Premenopausal Breast Cancer Patients With Tumors not Expressing Estrogen Receptors J. Clin. Oncol., February 1, 2000; 18(3): 584 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Miller, W. McCaskill-Stevens, J. Sisk, D. M. Loesch, F. Monaco, R. Seshadri, and G. W. Sledge Jr Combination Versus Sequential Doxorubicin and Docetaxel as Primary Chemotherapy for Breast Cancer: A Randomized Pilot Trial of the Hoosier Oncology Group J. Clin. Oncol., October 1, 1999; 17(10): 3033 - 3037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Dong, J. Yoneda, R. Kumar, and I. J. Fidler Angiostatin-mediated Suppression of Cancer Metastases by Primary Neoplasms Engineered to Produce Granulocyte/Macrophage Colony-stimulating Factor J. Exp. Med., August 17, 1998; 188(4): 755 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.R. Siewert, H.J. Stein, and U. Fink Multimodality Therapy for Esophageal Cancer Oncologist, August 1, 1996; 1(4): 210 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Teicher, T. Herman, S. Holden, Y. Wang, M. Pfeffer, J. Crawford, and E Frei 3rd Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo Science, March 23, 1990; 247(4949): 1457 - 1461. [Abstract] [PDF]
|
|
|
|
 |
|
 S. C. Formenti, B. Rosenstein, K. A. Skinner, and G. Jozsef T1 Stage Breast Cancer: Adjuvant Hypofractionated Conformal Radiation Therapy to Tumor Bed in Selected Postmenopausal Breast Cancer Patients—Pilot Feasibility Study Radiology, January 1, 2002; 222(1): 171 - 178. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
